Assessing the malignancy of suspicious breast microcalcifications: the role of contrast enhanced mammography
Authors:
- 12 April 2024
- journal article
- research article
- Published by Springer Nature in La radiologia medica
- Vol. 129 (6) , 855-863
Abstract
Purpose To assess the role of contrast-enhanced mammography (CEM) in predicting the malignancy of breast calcifications. Material and methods We retrospectively evaluated patients with suspicious calcifications (BIRADS 4) who underwent CEM and stereotactic vacuum-assisted biopsy (VAB) at our institution. We assessed the sensitivity (SE), specificity (SP), positive predictive value (PPV) and negative predictive value (NPV) of CEM in predicting malignancy of microcalcifications with a 95% confidence interval; we performed an overall analysis and a subgroup analysis stratified into group A-low risk (BIRADS 4a) and group B-medium/high risk (BIRADS 4b–4c). We then evaluated the correlation between enhancement and tumour proliferation index (Ki-67) for all malignant lesions. Results Data from 182 patients with 184 lesions were collected. Overall the SE of CEM in predicting the malignancy of microcalcifications was 0.70, SP was 0.85, the PPV was 0.82, the NPV was 0.76 and AUC was 0.78. SE in group A was 0.89, SP was 0.89, PPV was 0.57, NPV was 0.98 and AUC was 0.75. SE in group B was 0.68, SP was 0.80, PPV was 0.87, NPV was 0.57 and AUC was 0.75. Among malignant microcalcifications that showed enhancement (N = 52), 61.5% had Ki-67 ≥ 20% and 38.5% had low Ki-67 values. Among the lesions that did not show enhancement (N = 22), 90.9% had Ki-67 < 20% and 9.1% showed high Ki-67 values 20%. Conclusions The absence of enhancement can be used as an indicative parameter for the absence of disease in cases of low-suspicious microcalcifications, but not in intermediate-high suspicious ones for which biopsy remains mandatory and can be used to distinguish indolent lesions from more aggressive neoplasms, with consequent reduction of overdiagnosis and overtreatment.Keywords
This publication has 30 references indexed in Scilit:
- Should low-risk DCIS lose the cancer label? An evidence reviewBreast Cancer Research and Treatment, 2023
- Positive surgical margins after breast-conserving surgery for ductal carcinoma in-situ: does histologic grade or estrogen receptor status matter?Breast Cancer Research and Treatment, 2023
- Improving the Diagnostic Accuracy of Breast BI-RADS 4 Microcalcification-Only Lesions Using Contrast-Enhanced MammographyClinical Breast Cancer, 2021
- Can supplementary contrast-enhanced MRI of the breast avoid needle biopsies in suspicious microcalcifications seen on mammography? A systematic review and meta-analysisThe Breast, 2021
- The importance of early detection of calcifications associated with breast cancer in screeningBreast Cancer Research and Treatment, 2017
- Contrast-enhanced Spectral MammographyAcademic Radiology, 2017
- Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD studyEuropean Journal of Cancer, 2015
- Clinical utility of dual-energy contrast-enhanced spectral mammography for breast microcalcifications without associated mass: a preliminary analysisEuropean Radiology, 2015
- Diagnostic performance of dual-energy contrast-enhanced subtracted mammography in dense breasts compared to mammography alone: interobserver blind-reading analysisEuropean Radiology, 2014
- Contrast-enhanced spectral mammography in patients referred from the breast cancer screening programmeEuropean Radiology, 2014